GE Aerospace vs IDEXX Laboratories, Inc. — how do they compare? GE Aerospace trades at $365.58 (market cap $381.89B), while IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B). The key difference: GE Aerospace is far larger — about 8.3× IDEXX Laboratories, Inc.'s market cap, and GE Aerospace pays a 0.51% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| GE | IDXX | |
|---|---|---|
Market Cap | $381.89B | $46.22B |
Sector | Industrials | Health |
52-Week High | $381.22 | $766.68 |
52-Week Low | $265.93 | $526.44 |
Enterprise Value | $391.70B | $47.12B |
Dividend Yield | 0.51% | — |
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $366.70, down 0.91% with bullish technical momentum and strong fundamental performance. The stock shows robust earnings beats in recent quarters with Q2 2026 EPS of $2.02 exceeding expectations of $1.86. Revenue growth accelerated to $45.86 billion in 2025 with net income margin improving to 17.72%. Analyst consensus remains strongly positive with 24 buy ratings and a $414.11 price target, representing 13% upside potential.
The outlook remains favorable with strong aerospace demand, defense contract wins, and expanding order backlog driving growth. Key risks include elevated valuation multiples (P/E 43.4, P/S 7.68) and potential execution challenges amid heavy investment in MRO and manufacturing expansion. The company's improving cash flow generation and strategic positioning in commercial engines and defense sectors support continued upside potential.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Trailing returns across standard periods
Latest headlines on both assets
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →